Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-cash Items (2019 - 2025)

Vivos Therapeutics (VVOS) has disclosed Non-cash Items for 5 consecutive years, with $100000.0 as the latest value for Q2 2023.

  • On a quarterly basis, Non-cash Items changed N/A to $100000.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $100000.0, a N/A change, with the full-year FY2022 number at $65.5 million, changed N/A from a year prior.
  • Non-cash Items was $100000.0 for Q2 2023 at Vivos Therapeutics, down from $65.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $65.5 million in Q4 2022 to a low of $100000.0 in Q2 2023.
  • A 5-year average of $8.9 million and a median of $3.1 million in 2020 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 29.22% in 2021; the steepest drop was 66.03% in 2021.
  • Vivos Therapeutics' Non-cash Items stood at $6.7 million in 2019, then tumbled by 53.7% to $3.1 million in 2020, then plummeted by 44.77% to $1.7 million in 2021, then skyrocketed by 3725.93% to $65.5 million in 2022, then plummeted by 99.85% to $100000.0 in 2023.
  • Per Business Quant, the three most recent readings for VVOS's Non-cash Items are $100000.0 (Q2 2023), $65.5 million (Q4 2022), and $2.0 million (Q1 2022).